rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19

被引：6

作者：

Esmagambetov, Ilias B. ^{[1
]}

Ryabova, Ekaterina I. ^{[1
]}

Derkaev, Artem A. ^{[1
]}

Shcheblyakov, Dmitry V. ^{[1
]}

Dolzhikova, Inna V. ^{[1
]}

Favorskaya, Irina A. ^{[1
]}

Grousova, Daria M. ^{[1
]}

Dovgiy, Mikhail A. ^{[1
]}

Prokofiev, Vladimir V. ^{[1
]}

Gosudarev, Andrey I. ^{[1
]}

Byrikhina, Daria V. ^{[1
]}

Zorkov, Ilia D. ^{[1
]}

Iliukhina, Anna A. ^{[1
]}

Kovyrshina, Anna V. ^{[1
]}

Shelkov, Artem Y. ^{[1
]}

Naroditsky, Boris S. ^{[1
]}

Logunov, Denis Y. ^{[1
]}

Gintsburg, Alexander L. ^{[1
]}

机构：

[1] Minist Hlth Russian Federat, Fed State Budget Inst, Natl Res Ctr Epidemiol & Microbiol, Moscow, Russia

来源：

FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷

关键词：

recombinant adeno-associated viral vector (rAAV); single-domain antibodies; VHH; COVID-19; SARS-CoV-2; passive immunization; prophylaxis; VACCINE;

D O I：

10.3389/fimmu.2023.1129245

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In contrast, drugs based on monoclonal antibodies, enable rapid passive immunization and therefore can be used for emergency pre- and post-exposure prophylaxis of COVID-19. However rapid elimination of antibody-based drugs from the circulation limits their usage for prolonged pre-exposure prophylaxis. MethodsIn current work we developed a recombinant adeno-associated viral vector (rAAV), expressing a SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibody P2C5 fused with a human IgG1 Fc fragment (P2C5-Fc) using methods of molecular biotechnology and bioprocessing. Results and discussionsA P2C5-Fc antibody expressed by a proposed rAAV (rAAV-P2C5-Fc) was shown to circulate within more than 300 days in blood of transduced mice and protect animals from lethal SARS-CoV-2 virus (B.1.1.1 and Omicron BA.5 variants) lethal dose of 10(5) TCID50. In addition, rAAV-P2C5-Fc demonstrated 100% protective activity as emergency prevention and long-term prophylaxis, respectively. It was also demonstrated that high titers of neutralizing antibodies to the SARS-CoV-2 virus were detected in the blood serum of animals that received rAAV-P2C5-Fc for more than 10 months from the moment of administration.Our data therefore indicate applicability of an rAAV for passive immunization and induction of a rapid long-term protection against various SARS-CoV-2 variants.

引用

页数：13

共 30 条

[1] Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice against Influenza Virus
Adam, Virginie S.
Crosariol, Marco
Kumar, Sachin
Ge, Moyar Q.
Czack, Sarah E.
Roy, Soumitra
Haczku, Angela
Tretiakova, Anna
Wilson, James M.
Limberis, Maria P.
[J]. CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (11) : 1528 - 1533
[2] [Anonymous], COR DIS COVID 19 PAN
[3] Broad protection against influenza infection by vectored immunoprophylaxis in mice
Balazs, Alejandro B.
Bloom, Jesse D.
Hong, Christin M.
Rao, Dinesh S.
Baltimore, David
[J]. NATURE BIOTECHNOLOGY, 2013, 31 (07) : 647 - U110
[4] Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Casazza, Joseph P.
Cale, Evan M.
Narpala, Sandeep
Yamshchikov, Galina, V
Coates, Emily E.
Hendel, Cynthia S.
Novik, Laura
Holman, LaSonji A.
Widge, Alicia T.
Apte, Preeti
Gordon, Ingelise
Gaudinski, Martin R.
Conan-Cibotti, Michelle
Lin, Bob C.
Nason, Martha C.
Trofymenko, Olga
Telscher, Shinyi
Plummer, Sarah H.
Wycuff, Diane
Adams, William C.
Pandey, Janardan P.
McDermott, Adrian
Roederer, Mario
Sukienik, Avery N.
O'Dell, Sijy
Gall, Jason G.
Flach, Britta
Terry, Travis L.
Choe, Misook
Shi, Wei
Chen, Xuejun
Kaltovich, Florence
Saunders, Kevin O.
Stein, Judy A.
Doria-Rose, Nicole A.
Schwartz, Richard M.
Balazs, Alejandro B.
Baltimore, David
Nabel, Gary J.
Koup, Richard A.
Graham, Barney S.
Ledgerwood, Julie E.
Mascola, John R.
[J]. NATURE MEDICINE, 2022, 28 (05) : 1022 - +
[5] Centers for Medicare & Medicaid Services, ABOUT US
[6] Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
Del Rosario, Joanne Marie M.
Smith, Matthew
Zaki, Kam
Risley, Paul
Temperton, Nigel
Engelhardt, Othmar G.
Collins, Mary
Takeuchi, Yasuhiro
Hufton, Simon E.
[J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
[7] rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
Derkaev, Artem A. A.
Ryabova, Ekaterina I. I.
Esmagambetov, Ilias B. B.
Shcheblyakov, Dmitry V. V.
Godakova, Svetlana A. A.
Vinogradova, Irina D. D.
Noskov, Anatoly N. N.
Logunov, Denis Y. Y.
Naroditsky, Boris S. S.
Gintsburg, Alexander L. L.
[J]. FRONTIERS IN MICROBIOLOGY, 2022, 13
[8] Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection
Esmagambetov, I. B.
Shcheblyakov, D., V
Egorova, D. A.
Voronina, O. L.
Derkaev, A. A.
Voronina, D. V.
Popova, O.
Ryabova, E., I
Shcherbinin, D. N.
Aksenova, E., I
Semenov, A. N.
Kunda, M. S.
Ryzhova, N. N.
Zubkova, O., V
Tukhvatulin, A., I
Logunov, D. Yu
Naroditsky, B. S.
Borisevich, S., V
Gintsburg, A. L.
[J]. ACTA NATURAE, 2021, 13 (04): : 53 - 63
[9] Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
Favorskaya, Irina A.
Shcheblyakov, Dmitry V.
Esmagambetov, Ilias B.
Dolzhikova, Inna V.
Alekseeva, Irina A.
Korobkova, Anastasia I.
Voronina, Daria V.
Ryabova, Ekaterina I.
Derkaev, Artem A.
Kovyrshina, Anna V.
Iliukhina, Anna A.
Botikov, Andrey G.
Voronina, Olga L.
Egorova, Daria A.
Zubkova, Olga V.
Ryzhova, Natalia N.
Aksenova, Ekaterina I.
Kunda, Marina S.
Logunov, Denis Y.
Naroditsky, Boris S.
Gintsburg, Alexandr L.
[J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
[10] Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
Godakova, Svetlana A.
Noskov, Anatoly N.
Vinogradova, Irina D.
Ugriumova, Galina A.
Solovyev, Andrey I.
Esmagambetov, Ilias B.
Tukhvatulin, Amir I.
Logunov, Denis Y.
Naroditsky, Boris S.
Shcheblyakov, Dmitry V.
Gintsburg, Aleksandr L.
[J]. TOXINS, 2019, 11 (08)

← 1 2 3 →